| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | cCAT; GIG18; cAspAT; ASTQTL1 |
| WB Predicted band size | 46 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human GOT1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DcR1/CD263抗体的3-4篇代表性文献的简要总结(注：文献标题与作者为虚构示例，仅供格式参考)：
---
1. **文献名称**：*DcR1/TNFRSF10C as a Decoy Receptor in TRAIL-Induced Apoptosis Resistance*
**作者**：Sheridan, J.P. et al.
**摘要**：该研究首次阐明DcR1(CD263)作为诱骗受体在肿瘤坏死因子相关凋亡诱导配体(TRAIL)通路中的作用，揭示其在多种癌细胞中高表达可竞争性结合TRAIL，从而抑制凋亡信号传导，导致肿瘤耐药性产生。
2. **文献名称**：*Targeting CD263 with Monoclonal Antibodies Enhances TRAIL-Mediated Apoptosis in Cancer Cells*
**作者**：Ashkenazi, A. et al.
**摘要**：开发了一种靶向CD263的单克隆抗体，证明其可通过阻断DcR1与TRAIL的结合，恢复肿瘤细胞对TRAIL诱导凋亡的敏感性，为联合免疫治疗提供实验依据。
3. **文献名称**：*CD263 Expression in Immune Cells: Implications for Inflammatory Diseases*
**作者**：Wang, Y. et al.
**摘要**：探讨CD263在调节T细胞和巨噬细胞功能中的作用，发现其抗体干预可减轻过度炎症反应，提示DcR1抗体在治疗自身免疫性疾病中的潜力。
4. **文献名称**：*Structural Insights into DcR1 and Therapeutic Antibody Design*
**作者**：Pitti, R.M. et al.
**摘要**：通过解析DcR1的晶体结构，指导设计高特异性抗体，优化其与DcR1的结合表位，为开发靶向诱骗受体的精准疗法奠定基础。
---
**注**：以上文献为示例性内容，实际引用需查询PubMed、Web of Science等数据库获取真实文献。建议使用关键词“DcR1”、“CD263”、“TRAIL decoy receptor”、“antibody”进行检索，并结合近年研究筛选。
DcR1 (Decoy Receptor 1), also known as CD263 or TNFRSF10C, is a member of the tumor necrosis factor receptor (TNFR) superfamily. It functions as a decoy receptor that binds to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but lacks a functional death domain, thereby inhibiting TRAIL-mediated apoptosis. Unlike pro-apoptotic TRAIL receptors (DR4/TNFRSF10A and DR5/TNFRSF10B), DcR1 competes for ligand binding without activating downstream apoptotic signaling, modulating cellular sensitivity to TRAIL-induced cell death. This regulatory mechanism is critical in maintaining tissue homeostasis and has implications in cancer, autoimmune diseases, and immune evasion.
DcR1/CD263 antibodies are tools used to study the expression, localization, and functional roles of DcR1 in both physiological and pathological contexts. In cancer research, elevated DcR1 expression in tumors is associated with resistance to TRAIL-based therapies, making it a potential therapeutic target or biomarker. Antibodies targeting DcR1 can block its interaction with TRAIL, restoring apoptotic signaling in cancer cells, or serve as detection reagents in assays like flow cytometry, immunohistochemistry, or Western blotting. Additionally, DcR1’s role in immune regulation, particularly in T-cell activation and survival, has spurred interest in its involvement in inflammatory and autoimmune conditions. These antibodies thus contribute to unraveling DcR1’s dual roles in apoptosis modulation and immune signaling, offering insights for therapeutic development.
×
